Tesamorelin
Proper Handling
- Specifications: Lyophilized powder in 3 mL vial. Purity (>98%) meets or exceeds U.S. Pharmacopeia (USP) and National Formulary (USP-NF) regulations.
- Directions: Reconstitute with Bacteriostatic Water prior to use. Schedule a wellness consult or speak with your healthcare provider for proper dosage.
- Storage: In lyophilized form, the peptide is stable for 36 months. Protect from light. Refrigerate and use within 45 days after opening or reconstituting to prevent loss of potency.
Need to speak with a clinician?
Schedule a telehealth consultation with a practitioner specialized in peptide therapy, who will review your medical history and determine the best plan for you.
Tesamorelin is a growth-hormone-releasing analog that can increase IGF-1 levels in both men and women. Tesamorelin was approved for use in the United States as therapy to reduce excess abdominal fat. Tesamorelin is also being evaluated as therapy of insulin resistance, obesity and nonalcoholic fatty liver. Tesamorelin may also improve cognitive function for people with old age, and patients who suffer increase risk in Alzheimer’s disease due to mild cognitive impairment.
Potential Benefits
- Increase in the release of endogenous growth hormone
- Promotes muscle growth
- Helps with mood and stress resilience
- Slows down aging
- Enhances metabolic rate
- Improves sleep
- Promotes a balanced inflammatory response
- Improves bone density
CAS Number 218949-48-5
PubChem CID 16137828
Molecular Weight 5136 g/mol
Molecular Formula C221H366N72O67S
Synonyms Egrifta, TH 9507, TH-9507, UNII-MQG94M5EEO
Storage (Lyophilized)
At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years
This product is sold as a pure compound for research purposes only, unless prescribed by a licensed physician. This product comes in the form of lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Please refer to our terms and conditions prior to purchase.
Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.
The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.
- Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. https://www.ncbi.nlm.nih.gov/books/NBK548730/
- National Center for Biotechnology Information. "PubChem Compound Summary for CID 16137828, Egrifta" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Egrifta
- Bedimo, Roger. “Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.” HIV/AIDS (Auckland, N.Z.) vol. 3 (2011): 69-79. doi:10.2147/HIV.S14561. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218714/
- Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49-58. doi: 10.1111/j.1742-7843.2007.00008.x. PMID: 17214611. https://pubmed.ncbi.nlm.nih.gov/17214611/
- Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 6(12), e821–e830. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981288/
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Tesamorelin Effects on Liver Fat and Histology in HIV. https://clinicaltrials.gov/ct2/show/NCT02196831
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons. https://clinicaltrials.gov/ct2/show/record/NCT02572323
- Clemmons, D. R., Miller, S., & Mamputu, J. C. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PloS one, 12(6), e0179538. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
- Mar;133(3):274-6. doi: 10.1023/a:1015899003974. PMID: 12360351. https://pubmed.ncbi.nlm.nih.gov/12360351/
- Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide Epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006 Mar-Apr;20(2):253-7. PMID: 16634527. https://pubmed.ncbi.nlm.nih.gov/16634527/
- Pateyk AV, Baranchugova LM, Rusaeva NS, Obydenko VI, Kuznik BI. Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bull Exp Biol Med. 2013 Mar;154(5):681-5. doi: 10.1007/s10517-013-2029-0. PMID: 23658898. https://pubmed.ncbi.nlm.nih.gov/23658898/
- Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, Vengerin AA, Antoniuk-Shcheglova IA, Magdich LV. [Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people]. Adv Gerontol. 2007;20(1):74-85. Russian
- Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002 Aug;23(4):365-8. PMID: 12195242. https://pubmed.ncbi.nlm.nih.gov/12195242/
- Khavinson VKh, Morozov VG. Geroprotektornaia éffektivnost' timalina i épitalamina [Geroprotective effect of thymalin and Epithalamin]. Adv Gerontol. 2002;10:74-84. Russian. PMID: 12577695. https://pubmed.ncbi.nlm.nih.gov/12577695/
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of Epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006 Sep;142(3):356-9. English, Russian. doi: 10.1007/s10517-006-0365-z. PMID: 17426848. https://pubmed.ncbi.nlm.nih.gov/17426848/
Buy It With
Frequently Asked Questions
Tesamorelin
-
Recently the Tesamorelin peptide has grown increasingly popular for its ability to reduce body fat. FDA-approved in 2010 as a weight loss medication for HIV patients suffering from lipodystrophy, a condition that causes an accumulation of fat in the abdominal area, Tesamorelin has been viewed as an optimal weight loss treatment for non-HIV patients striving to manage their weight.
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) peptide. Unlike other GHRH analogs and even the natural form of the hormone found in the brain, Tesamorelin contains the entire GHRH amino acid sequence and a trans-3 hexenoic group to protect it from enzymatic degradation, which makes it more stable and extends its half-life.
-
Although Tesamorelin and Ipamorelin are both peptides that work to increase growth hormone production, the two peptides achieve this in different ways. While Tesamorelin activates growth hormone-releasing hormone (GHRH) receptors to stimulate the production and release of GHRH and IGF-1 to help reduce abdominal fat, Ipamorelin binds to ghrelin receptors in the pituitary gland to help stimulate the release of growth hormone in the blood to manage metabolism.
-
- Increase in the release of endogenous growth hormone
- Promotes muscle growth
- Helps with mood and stress resilience
- Slows down aging
- Enhances metabolic rate
- Improves sleep
- Promotes a balanced inflammatory response
- Improves bone density
Tesamorelin may also produce notable improvements in cognitive function for healthy adults and seniors with early signs of dementia. The peptide may also improve lipid profile and cardiovascular health by decreasing the intima-media thickness of the carotid arteries, which may help prevent atherosclerotic vascular disease.
-
Once Tesamorelin is inside the human body, the peptide binds to GHRH receptors to stimulate the pituitary gland into releasing growth hormone at a rate similar to the body’s naturally occurring GHRH traveling through the bloodstream. Once more growth hormone is released, it boosts metabolism and improves muscle growth, which helps to burn more calories and decrease body fat. The peptide can also help to increase insulin growth factor (IGF-1), which can help to lower glucose levels and further stimulate weight loss. As a result, Tesamorelin can help reduce visceral adipose tissue, leading to improved belly appearance, size, and waist circumference.
-
Tesamorelin may not be a viable treatment for everyone. Your physician may suggest that you avoid taking Tesamorelin if you have pre-existing conditions such as:
- Pituitary gland disorder
- Allergies to certain ingredients such as Mannitol
- Head pressure
- Lung complications
- Kidney disease
- Diabetes
- Adrenal gland disorder
- Epilepsy
- Heart disease
- High blood pressure
Potential patients with a history of cancer or benign or malignant tumors should also avoid using Tesamorelin. Inform your doctor if you’ve previously had radiation treatment or open heart surgery before taking Tesamorelin. Women who become pregnant during Tesamorelin treatment should discontinue the medication immediately after confirmation to avoid serious complications since using the medication may harm the unborn fetus and cause congenital disabilities.
-
Tesamorelin is commonly injected subcutaneously, making its use at risk for local redness, irritation, itching and swelling of the injection site. Other side effects that have been reported are:
- Depression
- Pain or numbness
- Muscle pain
- Vomiting
- Night sweats
- Joint inflammation
- Swelling and fluid retention
Remember, everyone reacts differently to medications like Tesamorelin due to individual physiological differences such as metabolism rate and overall health status. Tell your doctor if you have any side effects. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.
-
Tesamorelin is an injectable peptide administered subcutaneously through the fat. The most fatty parts of the body are the abdomen, side or back of upper arms, and front of thighs. Generally administered at 1-2 mg per day.
Schedule a telehealth appointment to determine the best plan for your health.
-
We're happy to help answer questions you may have, or refer you to a licensed healthcare professional for medical advice. Email us at care@somapeptides.com or schedule a telehealth appointment.
Your body, your journey .
Embarking on the journey to better health involves embracing holistic well-being through consultative care. Schedule an appointment to get ongoing support and a treatment plan for peptide therapy.